会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • FUNCTIONAL INFLUENZA VIRUS-LIKE PARTICLES (VLPS)
    • 功能性流感病毒颗粒(VLPS)
    • US20150306206A1
    • 2015-10-29
    • US14700577
    • 2015-04-30
    • NOVAVAX, INC.
    • Robin A. ROBINSONPeter M. PUSHKO
    • A61K39/145
    • A61K39/145A61K39/12A61K2039/5258A61K2039/575A61K2039/70C07H21/04C07K14/005C12N7/00C12N2760/16023C12N2760/16034C12N2760/16122C12N2760/16123C12N2760/16134
    • Recombinant influenza virus proteins, including influenza capsomers, subviral particles, virus-like particles (VLP), VLP complexes, and/or any portions of thereof, are provided as a vaccine for influenza viruses. The invention is based on the combination of two vaccine technologies: (1) intrinsically safe recombinant vaccine technology, and (2) highly immunogenic, self-assembled protein macromolecules embedded in plasma membranes and comprised of multiple copies of influenza virus structural proteins exhibiting neutralizing epitopes in native conformations. More specifically, this invention relates to the design and production of functional homotypic and heterotypic recombinant influenza virus-like particles (VLPs) comprised of recombinant structural proteins of human influenza virus type A/Sydney/5/94 (H3N2) and/or avian influenza virus type A/Hong Kong/1073/99 (H9N2) in baculovirus-infected insect cells and their application as a vaccine in the prevention of influenza infections and as a laboratory reagent for virus structural studies and clinical diagnostics.
    • 提供重组流感病毒蛋白,包括流行性感冒病毒,亚病毒颗粒,病毒样颗粒(VLP),VLP复合物和/或其任何部分作为流感病毒疫苗。 本发明基于两种疫苗技术的组合:(1)本质安全的重组疫苗技术,和(2)高度免疫原性的,自组装的蛋白质大分子,其包埋在质膜中,并且包含表现中和表位的流感病毒结构蛋白的多个拷贝 在原生构象。 更具体地说,本发明涉及由人流感病毒A型/悉尼/ 5/94(H3N2)和/或禽流感的重组结构蛋白构成的功能同型和异型重组流感病毒样颗粒(VLPs)的设计和生产 病毒A型/香港/ 1073/99(H9N2)在杆状病毒感染昆虫细胞中的应用,并将其作为疫苗用于预防流感感染和作为病毒结构研究和临床诊断的实验室试剂。